QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DCD.C. 20549

FORM 8-K

CURRENT ~~REPORTPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934~~REPORT

~~Date~~ ofPursuant ~~Report~~ to Section 13 OR 15(~~Date~~d) of ~~earliest~~The ~~event~~Securities ~~reported): February~~Exchange ~~29,~~Act ~~2008~~of 1934

~~MILLENNIUM~~Date ~~PHARMACEUTICALS,~~of ~~INC.~~Report (~~Exact~~Date ~~name~~ of ~~registrant~~earliest asevent ~~specified~~reported): inApril 10, ~~its charter)~~2008

Delaware	0-28494	04-3177038
(State or other jurisdictionof incorporation)	(Commission file number)	(IRS EmployerIdentification No.)

Millennium Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)

40Delaware ~~Landsdowne~~(State ~~StreetCambridge,~~or ~~Massachusetts~~Other ~~02139 (Address~~Jurisdiction of ~~principal~~Incorporation) ~~executive~~000-28494 ~~offices~~(Commission File Number) 04-3177038 (~~zip~~IRS ~~code~~Employer Identification No.)

(617) 679-7000 (Registrant's telephone number, including area code)

40 Landsdowne Street Cambridge, Massachusetts		02139
(Address of Principal Executive Offices)		(Zip Code)

~~Not applicable~~ 617-679-7000 (~~Former~~Registrant's ~~name~~telephone ornumber, ~~former~~including ~~address~~area ~~if changed since last report~~code)

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o: Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o: Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o: Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d- Item 2~~(b) under the Exchange Act (17 CFR 240~~.~~14d-2(b))~~02 Results of ~~Pre-commencement~~Operations ~~communications~~and ~~pursuant~~Financial ~~to Rule 13e-4(c) under the Exchange Act (17 CFR 240~~Condition.~~13e-4(c))~~

~~Item 7.01 Regulation~~ On FDApril 10, ~~Disclosure~~2008, Millennium Pharmaceuticals issued a press release to report the U.S. net sales of its principal product, VELCADE, for the quarter ended March 31, 2008. The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

~~Millennium~~ The information ~~Pharmaceuticals,~~in ~~Inc~~this Item 2.02 ~~(the “Company”)~~shall isnot ~~providing~~be ~~information~~deemed ~~about~~"filed" ~~January~~for ~~2008~~purposes ~~VELCADE®~~of Section 18 of the Securities Exchange Act of 1934 (~~bortezomib~~the "Exchange Act") or otherwise subject to ~~for~~the ~~Injection~~liabilities ~~U.S.~~of ~~sales~~that ~~data~~section, asnor ~~reported~~shall it be deemed incorporated by ~~IMS~~reference ~~Health~~in ~~Incorporated~~any ~~(“IMS”)~~filing ~~a third-party~~under ~~pharmaceutical~~the ~~information~~Securities ~~and~~Act ~~consulting~~of ~~company~~1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

While the Company typically does not comment on IMS sales data, the Company believes it is important to remind the public that there have been frequent and significant discrepancies in IMS data relative to actual VELCADE sales. The Company has noted these discrepancies on a monthly and quarterly basis, both in terms of direction and magnitude of change.

The Company is also confirming its 2008 VELCADE U.S. net sales guidance of $320 million to $345 million, representing 20 percent to 30 percent growth over 2007, as originally stated in January 2008. The Company also wishes to notify the public that the growth drivers that accelerated VELCADE U.S. sales in 2007 continue to drive growth in VELCADE demand in 2008.

This Form 8-k contains “forward-looking statements,” including statements about the Company’s growth and development of products. Various important risks may cause the Company’s actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company’s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company’s products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

The information in this Item 7.01 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~registrant~~Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MILLENNIUM PHARMACEUTICALS, INC.(Registrant)
	MILLENNIUM PHARMACEUTICALS, INC.
Date: February 29, 2008	By	/s/ MARSHA H. FANUCCI
Date: April 10, 2008	By:	/s/ LAURIE B. KEATING Laurie B. Keating Senior Vice President and General Counsel
		Marsha H. Fanucci
		Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release of Millennium Pharmaceuticals, Inc. dated April 10, 2008

QuickLinks

Item 2.02 Results of Operations and Financial Condition.

SIGNATURE
EXHIBIT INDEX

Filing Compare · MILLENNIUM PHARMACEUTICALS INC